Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078003 | 0.89 | MET (0.49) | METRPS6KA3ALDH1A1MAPTHSD17B10 | |
| SCHEMBL11938838 | 0.82 | MET (0.66) | METALDH1A1KDM4EHPGD | |
| SCHEMBL12722398 | 0.79 | MET (0.67) | METRPS6KA3ALDH1A1MAPTHSD17B10 | |
| SCHEMBL561808 | 0.78 | MET (0.43) | METRPS6KA3ALDH1A1MAPTHSD17B10 | |
| SCHEMBL1077503 | 0.77 | MET (0.51) | METRPS6KA3ALDH1A1MAPTKDM4E | |
| SCHEMBL4993791 | 0.76 | MET (0.59) | METRPS6KA3ALDH1A1MAPTHSD17B10 | |
| SCHEMBL13685358 | 0.75 | MET (0.58) | METRPS6KA3ALDH1A1MAPTHSD17B10 | |
| SCHEMBL12722608 | 0.74 | MET (0.57) | METRPS6KA3ALDH1A1MAPTHSD17B10 | |
| Bay-474 SCHEMBL4994862 | 0.74 | MET (0.66) | METRPS6KA3ALDH1A1MAPTHSD17B10 | |
| SCHEMBL1583372 | 0.73 | MET (0.57) | METRPS6KA3ALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2451817-B1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2451817-B1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| EP-2451817-A1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003604-A1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011003604-A1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BMX, MET, ABL1 | MET 2/4885RPS6KA3 1483/4885ALDH1A1 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.